¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"continuous density gradient"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • spin density weighted image
    ½ºÇɹеµ°­Á¶¿µ»ó
  • shadow density
    ±×¸²ÀÚÀ½¿µ, Åõ¿µÀ½¿µ
  • very low density lipoprotein
    ÃÊÀú¹ÐµµÁöÁú´Ü¹éÁú
  • axial gradient
    üÃà±â¿ï±â, üÃà°æ»ç
  • active gradient shielding
    ´Éµ¿°æ»çÂ÷Æó
  • alveolar-arterial oxygen gradient
    ÆóÆ÷µ¿¸Æ°£»ê¼ÒºÐ¾ÐÂ÷
  • B1 field gradient
    ȸÀüÀÚÀå±â¿ï±â
  • background gradient
    ¹è°æ±â¿ï±â
  • bipolar gradient
    ¾ç±Ø±â¿ï±â, µÎ±Ø±â¿ï±â
  • bipolar velocity encoding gradient
    ¾ç±Ø¼ÓµµºÎȣȭ°æ»ç, µÎ±Ø¼ÓµµºÎȣȭ±â¿ï±â
  • constant gradient
    °íÁ¤±â¿ï±â
  • diffusion gradient pulse
    È®»ê°æ»ç¸Æ¹Ú
  • electric potential gradient
    ÀüÀ§±â¿ï±â
  • electrical gradient
    Àü±â±â¿ï±â
  • electrochemical gradient
    Àü±âÈ­Çбâ¿ï±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • proton density weighted image
    ¾çÀڹеµ°­Á¶¿µ»ó
  • spin density weighted image
    ½ºÇɹеµ°­Á¶¿µ»ó
  • active gradient shielding
    ´Éµ¿±â¿ï±âÂ÷Æó, ´Éµ¿°æ»çÂ÷Æó
  • alveolar-arterial oxygen gradient
    ÆóÆ÷µ¿¸Æ°£»ê¼ÒºÐ¾ÐÂ÷
  • axial gradient
    üÃà±â¿ï±â, üÃà°æ»ç
  • gradient refocused acquisition
    ±â¿ï±âÀçÃÊÁ¡È¹µæ
  • B1 field gradient
    ȸÀüÀÚÀå±â¿ï±â
  • background gradient
    ¹è°æ±â¿ï±â
  • bipolar gradient
    ¾ç±Ø±â¿ï±â, µÎ±Ø±â¿ï±â
  • bipolar velocity encoding gradient
    ¾ç±Ø¼ÓµµºÎȣȭ±â¿ï±â, µÎ±Ø¼ÓµµºÎȣȭ±â¿ï±â
  • constant gradient
    °íÁ¤±â¿ï±â
  • gradient coil
    ±â¿ï±âÄÚÀÏ, °æ»çÄÚÀÏ
  • gradient correction
    °æ»çµµ±³Á¤, ±â¿ï±â±³Á¤
  • shielded gradient coil
    Â÷Æó°æ»çÄÚÀÏ
  • diffusion gradient pulse
    È®»ê°æ»ç¸Æ¹Ú, È®»ê°æ»ç¸Æ¹Ú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • density
    À½¿µ, ¹Ðµµ, ÈæÈ­µµ
  • density dependent inhibition
    ¹ÐµµÀÇÁ¸ ÀúÇØ.
  • density difference
    À½¿µÂ÷
  • density, epitope
    Ç׿ø°áÁ¤±â¹Ðµµ
  • density, optical
    Èí±¤µµ
  • electron density
    ÀüÀڹеµ
  • electron density
    ÀüÀڹеµ(¡­ÚËöô).
  • energy flux density
    ¿¡³ÊÁö¼Ó¹Ðµµ
  • epitope density
    Ç׿ø°áÁ¤±â¹Ðµµ
  • familial high density lipoprotein def
    °¡Á·¼º °íºñÁ߸®Æ÷´Ü¹éÁú°áÇÌ Áõ.
  • flux density
    À¯µ¿ ¹Ðµµ
  • flux density
    ¼Ó¹Ðµµ
  • grain density
    ÀÔÀÚ<±×·¡ÀÎ>¹Ðµµ.
  • high electron density
    °íÀüÀڹеµ(ÍÔï³í­ÚËöô).
  • high-density lipoprotein
    °í¹ÐµµÁö¹æ´Ü¹é
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • shear gradient
    ½¬¾î ±¸¹è(ÎøÛÎ)
  • sucrose gradient centrifugation
    ½´Å©·Î½º ±¸¹è ¿ø½ÉºÐ¸®(ÎøÛÎêÀãýÝÂ×î)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • gradient refocused imaging
    °æ»çÀçÃÊÁ¡¿µ»ó
  • gradient shielding
    °æ»çÂ÷Æó
  • gradient slope
    °æ»ç±â¿ï±â
  • gradient spoiling
    °æ»çȸ¼Õ
  • imaging gradient
    ¿µ»ó°æ»ç(ÀÚ°è)
  • magnetic field gradient
    ÀÚÀå°æ»ç
  • magnetic field gradient vector
    ÀÚÀå°æ»çº¤ÅÍ
  • magnetic susceptibility gradient
    ÀÚ±âÈ­À²°æ»ç
  • magnetization prepared rapid acquisition gradient echo
    ÀÚÈ­Áغñ°í¼Ó°æ»ç¿¡ÄÚ È¹µæ
  • maximum gradient strength
    ÃÖ´ë°æ»ç°­µµ
  • motion compensation gradient
    ¿îµ¿º¸»ó°æ»ç
  • MP-RAGE [=magnetization prepared rapid acquisition gradient echo]
    ÀÚÈ­Áغñ°í¼Ó°æ»ç¿¡ÄÚȹµæ
  • out of phase gradient echo image
    Å»À§»ó°æ»ç¿¡ÄÚ¿µ»ó
  • peak gradient strength
    ÃÖ°í°æ»ç¼¼±â
  • phase encoding gradient
    À§»óºÎȣȭ°æ»çµµ(Àå)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MPGR multiple planar gradient recalled
MP-RAGE magnetization-prepared rapid gradient-echo
NEPHGE nonequilibrated pH gradient electrophoresis
PPG photoplethysmography; platelet proteoglycan; portal pressure gradient
PSG peak systolic gradient; phosphate, saline, and glucose; polysomnogram; presystolic gallop; pregnancy...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
GGE gradient gel electrophoresis
MP RAGE magnetization prepared rapid acquisition gradient echo
PG pressure gradient
SGE spoiled gradient echo
SPGR spoiled gradient echo
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 5
density-dependent <epidemiology> 1. Effects whose intensity changes with increasing population density.
2. Effects whose intensity increases with increasing population density, for example a mortality which becomes very high near a carrying capacity. Effects which become less pronounced at higher population sizes (perhaps the reduction in fecundity caused by the difficulty of mating) are sometimes called inverse density dependent. Density dependent effects are often a cause of nonlinearity in a model.
(05 Dec 1998)
density dependent inhibition of growth <cell culture> The phenomenon exhibited by most normal (anchorage dependent) animal cells in culture that stop dividing once a critical cell density is reached.
The critical density is considerably higher for most cells than the density at which a monolayer is formed, for this reason, most cell behaviourists prefer the term density dependent inhibition of growth as this avoids any confusion with contact inhibition of locomotion, a totally different phenomenon that is contact dependent.
(12 Jan 1998)
incidence density The person-time incidence rate.
(05 Mar 2000)
intermediate density lipoprotein Class of lipoproteins formed in degradation of very-low-density lipoproteins; about half are cleared quickly from the plasma into the liver by receptor-mediated endocytosis; the other half are degraded into low density lipoproteins.
(05 Mar 2000)
inverse density dependence <epidemiology> See density dependence.
(05 Dec 1998)
optical density 1. <chemistry, investigation> Absorbance is defined as a logarithmic function of the percent transmission of a wavelength of light through a liquid.
2. <microbiology> This can be used as a measure of the amount of light absorbed by a suspension of bacterial cells or a solution of an organic molecule, it is measured by a colourimeter or spectrophotometer.
Absorbance values are used to plot the growth of bacteria in suspension cultures and to gauge the purity and concentration of molecules (such as proteins) in solution.
See: absorption.
(15 Jan 1998)
organismal density <microbiology> Number of organisms or items per unit area or volume.
(09 Oct 1997)
either particle flux density The particle fluence rate, or energy flux density, the energy fluence rate of intensity.
Compare: fluence.
(05 Mar 2000)
familial high density lipoprotein deficiency Familial high {density lipoprotein deficiency}; a heritable disorder of lipid metabolism characterised by almost complete absence from plasma of high density lipoproteins, and by storage of cholesterol esters in foam cells, tonsillar enlargement, an orange or yellow-gray colour of the pharyngeal and rectal mucosa, hepatosplenomegaly, lymph node enlargement, corneal opacity, and peripheral neuropathy; autosomal recessive inheritance.
Synonym: familial high {density lipoprotein deficiency}, Tangier disease.
Origin: G. An-, priv., + alpha, a, + lipoprotein + -aemia, blood
(05 Mar 2000)
flux density <radiobiology> Total amount of a quantity passing through a unit surface area in unit time
See: flux.
(09 Oct 1997)
low density lipoprotein <biochemistry> A lipoprotein substances (combination of a fat and a protein) which acts as a carrier for cholesterol and fats in the bloodstream.
High levels of low density lipoprotein are considered a positive risk factor for the development of coronary artery disease. Less than 130 mg/dl is desirable, 130 to 159 mg/dl is borderline high, over 160 is considered high.
Acronym: LDL
(10 Jan 1998)
low density lipoprotein receptor <biochemistry> A cell surface protein that mediates the endocytosis of low density lipoprotein by cells.
Genetic defects in low density lipoprotein receptors lead to abnormal serum levels of low density lipoprotein and hypercholesterolaemia.
(16 Mar 1998)
low-density lipoprotein receptors Receptors on the surface of cells, especially liver cells, which bind to low density lipoprotein and promote clearance of LDL from the plasma.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á